News blog

New cholesterol drugs make strides in clinical trials

The excitement around PCSK9 – a promising new protein target for cholesterol-lowering therapies – appears to be justified. This week, at the American College of Cardiology’s annual meeting in Washington DC, several pharmaceutical companies presented data from advanced clinical trials showing that monoclonal antibodies that target and degrade PCSK9 are effective at treating patients with high cholesterol, especially when combined with statins such as Lipitor. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE